Today we announce that we have received Halal Certification of our business models, commercial stage biomaterial products, and clinical and investigational stage cellular therapeutic programs, indicating that we have undergone rigorous assessment to determine that our innovative solutions are permissible or acceptable in accordance with Islamic, or Sharia, law.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of  Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the renowned Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Boston, USA on 8-12 November 2022.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today reported a corporate update and financial results for the third quarter of 2022.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab.

Today we announced the promotion of two senior executives and the formation of a new Executive Committee.

Today we announced the appointment of Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs. Dr. Kilcoyne brings over 15 years of clinical experience to Celularity, having previously served in R&D, medical affairs, and commercialization roles, primarily focused on oncology. He has a track record of advancing early-stage clinical programs through commercialization and will provide senior leadership to advance Celularity’s clinical pipeline toward U.S. Food and Drug Administration (FDA) approval.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET.

Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced publication of a study in Frontiers in Immunology describing the antiviral role of its placental-derived natural killer (NK) cells (CYNK) in IAV infections.

Today we announced that Celularity entered into a Pre-Paid Advance Agreement (the “Agreement”) with YA II PN, LTD (“Yorkville”), an affiliate of Yorkville Advisors Global, LP.

Today we announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will participate in fireside chats at the H.C. Wainwright 24th Annual Global Investment Conference and the Morgan Stanley 20th Annual Global Healthcare Conference.

Today we announced we are set to join the broad-market Russell 3000® and the Russell 2000® Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted June 3, 2022.

Today we announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.).

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its common stock at a purchase price of $7.40 per share and warrants to purchase 4,054,055 shares of its common stock at an exercise price of $8.25 per share (together the “Securities”) in a private placement priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $30.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will be exercisable immediately after the date of issuance and will expire five years following the initial issuance date. The closing of the offering and sale of the Securities is expected to occur on or about May 20, 2022, subject to the satisfaction of customary closing conditions.

Today we announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Today we reported fourth quarter and full year 2021 financial results and a corporate update.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies for cancer, infectious and degenerative diseases, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Andrew Pecora, M.D., President of Celularity, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 11:20am ET.